Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

27.93
+0.04000.14%
Post-market: 27.50-0.4300-1.54%18:24 EST
Volume:1.43M
Turnover:39.90M
Market Cap:1.44B
PE:-15.47
High:27.98
Open:27.76
Low:27.13
Close:27.89
52wk High:40.37
52wk Low:4.30
Shares:51.72M
Float Shares:46.19M
Volume Ratio:1.49
T/O Rate:3.10%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8055
EPS(LYR):-1.1490
ROE:-107.79%
ROA:-49.39%
PB:17.22
PE(LYR):-24.31

Loading ...

Crude Oil Gains 1%; Macy's Reports Strong Q3 Results

Benzinga
·
Dec 04, 2025

Capricor Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $60 From $24

THOMSON REUTERS
·
Dec 04, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Microsoft, Wyndham Hotels & Resorts, Daktronics

Reuters
·
Dec 03, 2025

BUZZ-Capricor jumps to 8-year high as cell therapy slows muscle-wasting disease

Reuters
·
Dec 03, 2025

Capricor Shares Gain Six-Fold to $40 After Co's Muscle Disorder Cell Therapy Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Dec 03, 2025

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:36 AM

Reuters
·
Dec 03, 2025

Sector Update: Health Care Stocks Advance Premarket Wednesday

MT Newswires Live
·
Dec 03, 2025

Capricor Therapeutics Exec Believes It Is "Prepared to Launch" Deramiocel - Conf Call

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Exec Says Co Passed Pre Licensing Inspection for San Diego Manufacturing Facility

THOMSON REUTERS
·
Dec 03, 2025

Capricor Exec Says FDA Indicated It Would Be Class Two Resubmission, Which Is About Six Months

THOMSON REUTERS
·
Dec 03, 2025

Capricor Exec Says Deramiocel Can Be Used With Any Therapeutics Currently Approved, Available or Under Clinical Development

THOMSON REUTERS
·
Dec 03, 2025

Capricor Exec Says Co Will Certainly Ask for Label for Skeletal Muscle Myopathy Based on Data

THOMSON REUTERS
·
Dec 03, 2025

Capricor Shares up 15% Premarket After Co's Muscle Disorder Cell Therapy Meets Late-Stage Trial Goal

THOMSON REUTERS
·
Dec 03, 2025

BRIEF-Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study

Reuters
·
Dec 03, 2025

Capricor eyes US nod for Duchenne cell therapy after success in key study

Reuters
·
Dec 03, 2025

Capricor Therapeutics' muscle disorder cell therapy succeeds in late-stage study

Reuters
·
Dec 03, 2025

Capricor Therapeutics Reports Positive Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy

Reuters
·
Dec 03, 2025

Capricor Therapeutics Inc - Deramiocel Maintains Favorable Safety Profile

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Announces Positive Topline Results From Pivotal Phase 3 Hope-3 Study of Deramiocel in Duchenne Muscular Dystrophy

THOMSON REUTERS
·
Dec 03, 2025

Capricor Therapeutics Inc - Company to Submit Response to Complete Response Letter

THOMSON REUTERS
·
Dec 03, 2025